NCT07819071Completed
EFFICACY AND TOLERANCE OF AN EYELID BALM IN COMBINATION WITH TACROLIMUS 0.1% IN PATIENTS WITH EYELID ATOPIC DERMATITIS
A RANDOMIZED COMPARATIVE SPLIT FACE STUDY TO EVALUATE THE EFFICACY AND TOLERANCE OF AN EYELID BALM IN COMBINATION WITH A TOPICAL CALCINEURIN INHIBITOR TREATMENT - TACROLIMUS 0.1 % - IN SUBJECTS WITH ATOPIC EYELID DERMATITIS
Source: ClinicalTrials.gov · Last updated 14 Sept 2026
Brief summary (registry, in English)
The aim of this study is to evaluate the tolerance and efficacy of a new emollient cream specifically dedicated to the eyelid area when applied in association with tacrolimus 0.1% in subjects suffering from eyelid Atopic Dermatitis.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 33 (actual)
- First submitted
- 4 Sept 2026
- Start date
- 3 Nov 2025
- Primary completion date
- 10 Jan 2026
- Lead sponsor
- Pierre Fabre Dermo Cosmetique
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT07819071
What you commit to
- Study type: Interventional
- Participants enrolled: 33
- From 3 Nov 2025 to the primary completion date, 10 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Female and Male
- Subjects from 18 to 65 years old
- Subject who has signed his/her written informed consent for his/her participation in the study and a photograph authorization
- Subject presenting atopic dermatitis according to the definition of "the U.K Working Party's Diagnostic Criteria for Atopic Dermatitis."
- Subjects with Atopic Eyelid Dermatitis with bilateral involvement of similar surface and same intensity (no more than 1 point of difference in the total L-SCORAD)
- Subjects with atopic dermatitis flare-up on the eyelids requiring topical calcineurin inhibitor treatment (tacrolimus 0.1%) and initiated within the last 24 hours
- Subject who has started a topical calcineurin inhibitor treatment (tacrolimus 0.1%; twice a day) on the eyelids within the last 24 hours prior to the inclusion
- Subject who used the same cleansing product on face the same make-up (if applicable) for at least two weeks before inclusion and remain stable during the whole study.
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centrum Medyczne "Tu Się Leczy" Norwida Coordinator of this site? Confirm its status | Gdansk | Poland | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.